Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

NxStage Medical Inc raises Q4, FY 2013 revenue guidance; sees Q4, FY 2013 net income guidance within prior range


Monday, 13 Jan 2014 04:05pm EST 

NxStage Medical Inc:Says for Q4 2013 it expects to deliver total revenue of about $69 million, above the top end of its previously announced guidance range for revenue to be between $67.0 to $68.5 million.Says for FY 2013, it expects to deliver total revenue of about $263 million, above the top end of its previously announced guidance range for revenue to be between $261.0 to $262.5 million.Says it also expects net loss for Q4 2013 and FY 2013 to be within its previous announced guidance ranges of $5 to $6 million and $18.5 to $19.5 million, respectively.Q4 2013 revenue of $68 million and net income of $(6) million - Thomson Reuters I/B/E/S Estimates.FY 2013 revenue of $262 million and net income of $(19.0) million - Thomson Reuters I/B/E/S Estimates. 

Company Quote

17.53
0.19 +1.10%
2:33pm EST